119 related articles for article (PubMed ID: 34907122)
1. TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN: Functional and Anatomical Impact on Patients With Neovascular Age-Related Macular Degeneration.
Montesel A; Gigon A; Giacuzzo C; Mantel I; Eandi CM
Retina; 2022 Apr; 42(4):634-642. PubMed ID: 34907122
[TBL] [Abstract][Full Text] [Related]
2. [Impact of the French 2020 COVID-19 lockdown on the treatment and follow-up of patients with exudative age-related macular degeneration].
Auger A; Khanna RK; Bonicel P; Pisella PJ; Le Lez ML
J Fr Ophtalmol; 2023 Jun; 46(6):596-604. PubMed ID: 37248127
[TBL] [Abstract][Full Text] [Related]
3. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration.
Szegedi S; Ebner C; Miháltz K; Wachter T; Vécsei-Marlovits PV
BMC Ophthalmol; 2022 May; 22(1):228. PubMed ID: 35596203
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD.
Stattin M; Haas AM; Ahmed D; Graf A; Krepler K; Ansari-Shahrezaei S
Eur J Ophthalmol; 2022 Jul; 32(4):2312-2318. PubMed ID: 34726553
[TBL] [Abstract][Full Text] [Related]
5. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
[TBL] [Abstract][Full Text] [Related]
6. INTERNATIONAL IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON INTRAVITREAL THERAPY OUTCOMES: Fight Retinal Blindness Registry.
Zarranz-Ventura J; Nguyen V; Creuzot-Garcher C; Verbraak F; O Toole L; Invernizzi A; Viola F; Squirrel D; Barthelmes D; Gillies MC;
Retina; 2022 Apr; 42(4):616-627. PubMed ID: 34907129
[TBL] [Abstract][Full Text] [Related]
7. Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration.
Nassisi M; Pozzo Giuffrida F; Milella P; Ganci S; Aretti A; Mainetti C; Dell'Arti L; Mapelli C; Viola F
BMC Ophthalmol; 2023 Apr; 23(1):156. PubMed ID: 37069537
[TBL] [Abstract][Full Text] [Related]
8. Results of the treatment of patients with exudative AMD during the COVID-19 pandemic.
Arruabarrena C; Montejano-Milner R; de Aragón F; Allendes G; Teus MA
Arch Soc Esp Oftalmol (Engl Ed); 2022 Apr; 97(4):184-190. PubMed ID: 35523464
[TBL] [Abstract][Full Text] [Related]
9. [Impact of the SARS-CoV-2 pandemic on diabetic macular edema and prognostic factors].
Khodriss C; El Harch I; Bennis A; Chraibi F; El Fakir S; Abdellaoui M; Tachfouti N; Benatiya Andaloussi I
J Fr Ophtalmol; 2021 Nov; 44(9):1313-1318. PubMed ID: 34538511
[TBL] [Abstract][Full Text] [Related]
10. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
Rahimy E; Rayess N; Ho AC; Regillo CD
Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
[TBL] [Abstract][Full Text] [Related]
11. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
12. Socioeconomic status and visual outcome in patients with neovascular age-related macular degeneration.
Levinger N; Beykin G; Grunin M; Almeida D; Levy J; Levine H; Averbukh E; Chowers I
Eur J Ophthalmol; 2021 May; 31(3):1094-1100. PubMed ID: 32363931
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity.
Ozkaya A; Alkin Z; Yazici AT; Demirok A
Retina; 2014 May; 34(5):853-9. PubMed ID: 24141904
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
Monés J; Biarnés M;
Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
[TBL] [Abstract][Full Text] [Related]
16. Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report.
Mollan SP; Fu DJ; Chuo CY; Gannon JG; Lee WH; Hopkins JJ; Hughes C; Denniston AK; Keane PA; Cantrell R
Br J Ophthalmol; 2023 Feb; 107(2):267-274. PubMed ID: 34518162
[TBL] [Abstract][Full Text] [Related]
17. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ
Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524
[TBL] [Abstract][Full Text] [Related]
18. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
[TBL] [Abstract][Full Text] [Related]
19. DELAYED FOLLOW-UP IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED UNDER UNIVERSAL HEALTH COVERAGE: Risk Factors and Visual Outcomes.
Rozon JP; Hébert M; Laverdière C; Lachance A; Bourgault S; Caissie M; Letartre L; Tourville E; Dirani A
Retina; 2022 Sep; 42(9):1693-1701. PubMed ID: 35504012
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration.
Heussen FM; Shao Q; Ouyang Y; Joussen AM; Müller B
Graefes Arch Clin Exp Ophthalmol; 2014 Jun; 252(6):909-15. PubMed ID: 24362854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
